Medicare Enrolled
Dr. Rohit Kapoor, M.D.
Hematology & Oncology · Live Oak, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kapoor from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kapoor?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kapoor
Dr. Rohit Kapoor is a hematology & oncology specialist in Live Oak, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kapoor performed 58,139 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Kapoor received a total of $28,981 from 96 pharmaceutical and/or device companies across 952 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kapoor is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 16% volume in TX
$28,981 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗58,139
Medicare services
Top 16% in TX for hematology & oncology
Not available
Unique patients (not deduplicated)
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 14,400 | $43 | $133 |
| Injection, granisetron hydrochloride, 100 mcg | 10,771 | $0 | $3 |
| Injection, docetaxel, 1 mg | 6,675 | $0 | $55 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
6,362 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,987 | $8 | $9 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
2,043 | $7 | $34 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,766 | $66 | $217 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
1,629 | $22 | $94 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 1,130 | $2 | $19 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
904 | $6 | $51 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
821 | $62 | $195 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
788 | $86 | $314 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
713 | $94 | $397 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
683 | $44 | $120 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 638 | $3 | $161 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
589 | $84 | $279 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
501 | $46 | $186 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
421 | $9 | $43 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
381 | $2 | $7 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
371 | $20 | $90 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
336 | $83 | $1,161 |
| Iron dextran injection, 50 mg An injection containing 50 mg of iron dextran administered to the patient. |
328 | $14 | $35 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
266 | $0 | $1 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
247 | $2 | $35 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
208 | $9 | $65 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
208 | $2 | $5 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
197 | $1 | $2 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
173 | $11 | $66 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
171 | $7 | $668 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
162 | $78 | $320 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
160 | $39 | $109 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
148 | $47 | $208 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
140 | $4 | $18 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
120 | $71 | $186 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
106 | $24 | $161 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
105 | $14 | $52 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
97 | $40 | $180 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
81 | $1 | $2 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
71 | $76 | $262 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
57 | $127 | $503 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
57 | $134 | $528 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
49 | $15 | $63 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
36 | $21 | $159 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
27 | $102 | $359 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
16 | $128 | $509 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
6.1% high complexity
73.9% medium
20.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$28,981
Total received (2018-2024)
Avg $4,140/year across 7 years
Top 16% in TX for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
96
Companies
952
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$11,308
2023
$8,396
2022
$2,679
2021
$2,255
2020
$1,637
2019
$1,508
2018
$1,198
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$2,405
Eisai Inc.
$1,870
Daiichi Sankyo Inc.
$1,501
Aveo Pharmaceuticals, Inc.
$923
Novartis Pharmaceuticals Corporation
$565
Astellas Pharma US Inc
$468
Merck Sharp & Dohme LLC
$442
Janssen Biotech, Inc.
$412
PFIZER INC.
$335
Incyte Corporation
$251
E.R. Squibb & Sons, L.L.C.
$193
Takeda Pharmaceuticals U.S.A., Inc.
$152
Genentech USA, Inc.
$138
SOBI, INC
$122
SEAGEN INC.
$100
Blueprint Medicines Corporation
$96
Regeneron Healthcare Solutions, Inc.
$95
Karyopharm Therapeutics Inc.
$92
Lilly USA, LLC
$82
GENZYME CORPORATION
$74
Gilead Sciences, Inc.
$66
Agios Pharmaceuticals, Inc.
$62
Rigel Pharmaceuticals, Inc.
$61
Celgene Corporation
$60
ABBVIE INC.
$57
Ipsen Biopharmaceuticals, Inc
$55
Bayer Healthcare Pharmaceuticals Inc.
$49
PUMA BIOTECHNOLOGY, INC.
$47
Azurity Pharmaceuticals, Inc.
$46
Stemline Therapeutics Inc.
$44
ARRAY BIOPHARMA INC
$42
EMD Serono, Inc.
$32
GlaxoSmithKline, LLC.
$31
Sumitomo Pharma America, Inc.
$30
Amgen Inc.
$29
TAIHO ONCOLOGY, INC.
$27
Fresenius Kabi USA, LLC
$26
Boehringer Ingelheim Pharmaceuticals, Inc.
$26
ADC Therapeutics America, Inc.
$25
Sirtex Medical Inc
$25
SERVIER PHARMACEUTICALS LLC
$24
JAZZ PHARMACEUTICALS INC.
$23
Spectrum Pharmaceuticals Inc.
$23
Mirati Therapeutics, Inc.
$22
Alexion Pharmaceuticals, Inc.
$20
Acrotech Biopharma Inc.
$20
TerSera Therapeutics LLC
$17
Top 3 companies account for 51.1% of 2024 payments
All-time payments by company (2018-2024) ›
Seagen Inc.
$5,088
AstraZeneca Pharmaceuticals LP
$2,925
Eisai Inc.
$2,415
Novartis Pharmaceuticals Corporation
$1,603
Daiichi Sankyo Inc.
$1,548
Janssen Biotech, Inc.
$1,531
Aveo Pharmaceuticals, Inc.
$943
Merck Sharp & Dohme LLC
$918
Astellas Pharma US Inc
$872
E.R. Squibb & Sons, L.L.C.
$847
PFIZER INC.
$650
Incyte Corporation
$642
GENZYME CORPORATION
$604
Merck Sharp & Dohme Corporation
$585
Amgen Inc.
$566
Genentech USA, Inc.
$527
Takeda Pharmaceuticals U.S.A., Inc.
$507
Lilly USA, LLC
$283
SOBI, INC
$208
Karyopharm Therapeutics Inc.
$202
Rigel Pharmaceuticals, Inc.
$197
EISAI INC.
$195
AVEO Pharmaceuticals, Inc.
$191
Janssen Pharmaceuticals, Inc
$190
Dova Pharmaceuticals
$176
PUMA BIOTECHNOLOGY, INC.
$175
Regeneron Healthcare Solutions, Inc.
$169
Celgene Corporation
$161
ABBVIE INC.
$160
MorphoSys, US Inc.
$145
EMD Serono, Inc.
$139
Foundation Medicine, Inc.
$138
TerSera Therapeutics LLC
$136
Bayer Healthcare Pharmaceuticals Inc.
$134
Epizyme, Inc.,
$132
Global Blood Therapeutics, Inc.
$129
Puma Biotechnology, Inc.
$126
Ipsen Biopharmaceuticals, Inc
$120
Agios Pharmaceuticals, Inc.
$111
Teva Pharmaceuticals USA, Inc.
$111
Blueprint Medicines Corporation
$110
Helsinn Therapeutics (U.S.), Inc.
$103
GlaxoSmithKline, LLC.
$100
SEAGEN INC.
$100
ADC Therapeutics America, Inc.
$99
Gilead Sciences, Inc.
$99
Bayer HealthCare Pharmaceuticals Inc.
$94
Sobi, Inc
$79
Boehringer Ingelheim Pharmaceuticals, Inc.
$77
Mirati Therapeutics, Inc.
$74
CTI BioPharma Corp.
$73
Lexicon Pharmaceuticals, Inc.
$71
SERVIER PHARMACEUTICALS LLC
$67
Kyowa Kirin, Inc.
$62
Alexion Pharmaceuticals, Inc.
$61
AMAG Pharmaceuticals, Inc.
$59
Stemline Therapeutics Inc.
$57
Alnylam Pharmaceuticals Inc.
$56
TAIHO ONCOLOGY, INC.
$54
Sun Pharmaceutical Industries Inc.
$53
Sumitomo Pharma America, Inc.
$47
Spectrum Pharmaceuticals Inc.
$46
Azurity Pharmaceuticals, Inc.
$46
Jazz Pharmaceuticals Inc.
$44
ARRAY BIOPHARMA INC
$42
Seattle Genetics, Inc.
$42
Acrotech Biopharma LLC
$36
Sirtex Medical Inc
$36
Secura Bio, Inc.
$35
Coherus Biosciences Inc.
$34
BeiGene USA, Inc.
$31
Fennec Pharmaceuticals, Inc.
$31
Taiho Oncology, Inc.
$30
Tactile Systems Technology Inc
$29
Clovis Oncology, Inc.
$28
Emmaus Medical, Inc.
$27
Fresenius Kabi USA, LLC
$26
TESARO, Inc.
$26
Mylan Institutional Inc.
$25
Roche Diagnostics Corporation
$24
JAZZ PHARMACEUTICALS INC.
$23
Pharmacyclics LLC, An AbbVie Company
$22
Acrotech Biopharma Inc.
$20
Servier Pharmaceuticals LLC
$19
Kite Pharma, Inc.
$18
Genmab U.S., Inc.
$17
EUSA Pharma (US) LLC
$15
Innate Pharma, Inc
$14
Medtronic USA, Inc.
$14
Sandoz Inc.
$14
Exelixis Inc.
$14
SECURA BIO, INC.
$13
Verastem, Inc.
$13
Array BioPharma Inc.
$12
AbbVie, Inc.
$12
NOVARTIS PHARMACEUTICALS CORPORATION
$9
Top 3 companies account for 36.0% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Alecensa · BAVENCIO · BELEODAQ · BENDEKA · BLENREP · BOSULIF · BRUKINSA · Bavencio · Blincyto · Braftovi · CABLIVI · CALQUENCE · CHANTIX · COPIKTRA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMEND · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Endari · Enhertu · Epkinly · Erleada · FARXIGA · FARYDAK · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · Flexitouch Plus · Folotyn · Fulphila · GILOTRIF · GIVLAARI · HYQVIA · Halaven · IBRANCE · ICLUSIG · IM NAILS · IMBRUVICA · IMFINZI · INLYTA · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lumoxiti · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · Nplate · Nubeqa · ODOMZO (sonidegib) capsules · OJJAARA · ONPATTRO · OPDIVO · ORGOVYX · OSTEOCOOL RF ABLATION · OXBRYTA · Odomzo · Ogivri · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PYRUKYND · Padcev · Pedmark · Perjeta · Pomalyst · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNAGIS · Somatuline Depot · Stimufend · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · Tavalisse · Tecentriq · Tibsovo · Trodelvy · Truxima · ULTOMIRIS · Udenyca · VALCHLOR · VENCLEXTA · VERZENIO · VIVIMUSTA · VOTRIENT · Vectibix · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · ZARXIO · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
59
County median income
$70,571
Nearest hospital to ZIP centroid (approximate)
LAUREL RIDGE TREATMENT CENTER
5.9 mi
5.9 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kapoor is a mixed practice specialist, with above-average Medicare volume (top 16% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kapoor experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Kapoor performed 14,400 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Kapoor receive payments from pharmaceutical companies?
Yes. Dr. Kapoor received a total of $28,981 from 96 companies across 952 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kapoor's costs compare to other hematology & oncology specialists in Live Oak?
Dr. Kapoor's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kapoor) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Live Oak
Browse hematology & oncology specialists in Live Oak ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Seagen Inc. Payments to Doctors
See all physicians who received payments from Seagen Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Eisai Inc. Payments to Doctors
See all physicians who received payments from Eisai Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology